PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q3 2017 13F Holders as of 30 Sep 2017

Type / Class
Equity / COM
Total 13F shares
57,900,241
Share change
-3,227,702
Total reported value
$427,578,828
Put/Call ratio
147%
Price per share
$7.36
Number of holders
132
Value change
-$21,543,169
Number of buys
65
Number of sells
62

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q3 2017

As of 30 Sep 2017, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 132 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 57,900,241 shares. The largest 10 holders included FEDERATED INVESTORS INC /PA/, BlackRock Inc., VANGUARD GROUP INC, EAGLE ASSET MANAGEMENT INC, STATE STREET CORP, BAKER BROS. ADVISORS LP, FMR LLC, PINNACLE ASSOCIATES LTD, ARDSLEY ADVISORY PARTNERS, and RICE HALL JAMES & ASSOCIATES, LLC. This page lists 132 institutional shareholders reporting positions in this security for the Q3 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.